136 related articles for article (PubMed ID: 14644994)
1. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Podar K; Catley LP; Tai YT; Shringarpure R; Carvalho P; Hayashi T; Burger R; Schlossman RL; Richardson PG; Pandite LN; Kumar R; Hideshima T; Chauhan D; Anderson KC
Blood; 2004 May; 103(9):3474-9. PubMed ID: 14644994
[TBL] [Abstract][Full Text] [Related]
2. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
4. Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.
Dev IK; Dornsife RE; Hopper TM; Onori JA; Miller CG; Harrington LE; Dold KM; Mullin RJ; Johnson JH; Crosby RM; Truesdale AT; Epperly AH; Hinkle KW; Cheung M; Stafford JA; Luttrell DK; Kumar R
Br J Cancer; 2004 Oct; 91(7):1391-8. PubMed ID: 15328520
[TBL] [Abstract][Full Text] [Related]
5. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS).
Tanimoto T; Jin ZG; Berk BC
J Biol Chem; 2002 Nov; 277(45):42997-3001. PubMed ID: 12226078
[TBL] [Abstract][Full Text] [Related]
6. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
7. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells.
Kanno S; Oda N; Abe M; Terai Y; Ito M; Shitara K; Tabayashi K; Shibuya M; Sato Y
Oncogene; 2000 Apr; 19(17):2138-46. PubMed ID: 10815805
[TBL] [Abstract][Full Text] [Related]
8. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.
Seetharam L; Gotoh N; Maru Y; Neufeld G; Yamaguchi S; Shibuya M
Oncogene; 1995 Jan; 10(1):135-47. PubMed ID: 7824266
[TBL] [Abstract][Full Text] [Related]
9. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
10. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer.
Itakura J; Ishiwata T; Shen B; Kornmann M; Korc M
Int J Cancer; 2000 Jan; 85(1):27-34. PubMed ID: 10585578
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
Podar K; Tai YT; Lin BK; Narsimhan RP; Sattler M; Kijima T; Salgia R; Gupta D; Chauhan D; Anderson KC
J Biol Chem; 2002 Mar; 277(10):7875-81. PubMed ID: 11751905
[TBL] [Abstract][Full Text] [Related]
12. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
[TBL] [Abstract][Full Text] [Related]
13. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
Hideshima T; Akiyama M; Hayashi T; Richardson P; Schlossman R; Chauhan D; Anderson KC
Blood; 2003 Jan; 101(2):703-5. PubMed ID: 12393542
[TBL] [Abstract][Full Text] [Related]
14. Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells.
Zingg D; Riesterer O; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Cancer Res; 2004 Aug; 64(15):5398-406. PubMed ID: 15289348
[TBL] [Abstract][Full Text] [Related]
15. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF.
Endo A; Fukuhara S; Masuda M; Ohmori T; Mochizuki N
J Recept Signal Transduct Res; 2003; 23(2-3):239-54. PubMed ID: 14626450
[TBL] [Abstract][Full Text] [Related]
17. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Hamasaki M; Hideshima T; Tassone P; Neri P; Ishitsuka K; Yasui H; Shiraishi N; Raje N; Kumar S; Picker DH; Jacob GS; Richardson PG; Munshi NC; Anderson KC
Blood; 2005 Jun; 105(11):4470-6. PubMed ID: 15705788
[TBL] [Abstract][Full Text] [Related]
18. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
Le Gouill S; Podar K; Amiot M; Hideshima T; Chauhan D; Ishitsuka K; Kumar S; Raje N; Richardson PG; Harousseau JL; Anderson KC
Blood; 2004 Nov; 104(9):2886-92. PubMed ID: 15217829
[TBL] [Abstract][Full Text] [Related]
19. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells.
Chou MT; Wang J; Fujita DJ
BMC Biochem; 2002 Dec; 3():32. PubMed ID: 12509223
[TBL] [Abstract][Full Text] [Related]
20. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1.
Landgren E; Schiller P; Cao Y; Claesson-Welsh L
Oncogene; 1998 Jan; 16(3):359-67. PubMed ID: 9467961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
